Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | Director · CHAIRMAN OF THE BOARD AND CEO | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 178,737 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 36,523 · Balance 178,737 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2020 Filed Feb 24, 2020 18:01 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002133 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,654 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 16:56 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 3,206 | $79.41 | $254,588.46 |
DisclosureSEC source: 0001179110-19-003084 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,913 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 54,517 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · derivative · entry 5 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,517 Underlying: Common Stock · 54,517 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,173 on February 21, 2020, 18,172 on February 21, 2021, and 18,172 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 4 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,119 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,634 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,924 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 17:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002364 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,229 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:31 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 4,294 | $119.43 | $512,853.46 |
DisclosureSEC source: 0001179110-18-003340 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,876 F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.40 to $119.501, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:31 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 2,387 | $118.26 | $282,286.62 |
DisclosureSEC source: 0001179110-18-003340 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,170 Read SEC document |
| February 20, 2018 Filed Feb 20, 2018 18:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 592 | $120.33 | $71,235.36 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,557 Read SEC document |
| February 20, 2018 Filed Feb 20, 2018 18:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 400 | $120.29 | $48,116.04 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,149 Read SEC document |
| February 19, 2018 Filed Feb 20, 2018 18:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 838 | $118.60 | $99,386.80 |
DisclosureSEC source: 0001179110-18-002429 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,549 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 8,030 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · derivative · entry 4 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,030 Underlying: Common Stock · 8,030 shares Expires 2028-02-14 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 2,677 on February 15, 2019, 2,676 on February 15, 2020, and 2,677 on February 15, 2021. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 3 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,387 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 2 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,677 F2 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 17:56 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 1,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002301 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,702 F1 · shares: Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2018. Read SEC document |
| September 28, 2017 Filed Sep 29, 2017 17:02 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 6,699 | $88.00 | $589,512.00 |
DisclosureSEC source: 0001179110-17-012766 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,007 Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 17:22 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon stock, $0.01 par value | 5,132 | $65.29 | $335,068.28 |
DisclosureSEC source: 0001179110-17-004442 · edgar.xml · nonDerivative · entry 1 Michael Robert A. · CIK 0001699914 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,706 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.